SynthesisBMJ open diabetes research & care2022
Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis.
Synthesis in BMJ open diabetes research & care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 65 citations in OpenAlex.
- Lifestyle Intervention With Smartphone App and isCGM for People at High Risk of Type 2 Diabetes: Randomized Trial.The Journal of clinical endocrinology and metabolism · 2024Trial
- A multicenter prospective evaluation of the benefits of Dexcom ONE + in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study.Acta diabetologica · 2026Article
- Cost-effectiveness of Freestyle Libre Systems for People with Type 2 Diabetes Mellitus on Basal Insulin Therapy in the Netherlands: An Economic Evaluation from a Societal Perspective Within a Publicly Funded Healthcare System.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Continuous glucose monitoring reveals high prevalence of hyperglycaemia in patients prior to pancreatic surgery: A pilot study.Journal of clinical & translational endocrinology · 2026Article
- Cost-Utility Analysis of FreeStyle Libre Systems in People with Type 2 Diabetes Mellitus on Treatment with Basal Insulin and Poor Glycemic Control in Spain.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group.Diabetes/metabolism research and reviews · 2025Review
- Narrative Review: Continuous Glucose Monitoring (CGM) in Older Adults with Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Article
- The role of advanced technologies in improving diabetes outcomes.The American journal of managed care · 2025Review
- Advances in Continuous Glucose Monitoring: Clinical Applications.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Removing barriers to management of adults with type 2 diabetes on insulin using continuous glucose monitoring in UK primary care practice: An expert consensus.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.Journal of managed care & specialty pharmacy · 2025Article
- Intermittent Use of Flash Glucose Monitoring Improves Glycemic Control in Chinese Older Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbADiabetologia · 2025Article
- Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure.Journal of managed care & specialty pharmacy · 2024Article
- Innovation is the driver behind quality improvements in diabetes care delivery.Journal of managed care & specialty pharmacy · 2024Article
- Best practices and rationale for expanding Medicaid access to continuous glucose monitoring.Journal of managed care & specialty pharmacy · 2024Article
- Advances in diabetes technology within the digital diabetes ecosystem.Journal of managed care & specialty pharmacy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvidence supporting use of continuous glucose monitoring in type 2 diabetes treated with basal insulin is unclear. This real-world study aimed to assess the impact on glycated hemoglobin (HbA1c) of flash glucose monitoring use in adults with type 2 diabetes managed with basal insulin. RESEARCH DESIGN AND
methodsMedical records were reviewed for adult individuals with type 2 diabetes using basal insulin for ≥1 year with or without additional antihyperglycemic medication, HbA1c 8.0%-12.0% prior to FreeStyle Libre Flash Glucose Monitoring use for ≥90 days and an HbA1c measurement recorded between 90 and 194 days after device use. Exclusion criteria included utilization of bolus insulin. Meta-analysis data are from the current study (USA) and a similar Canadian cohort.
resultsMedical record analysis (n=100) from 8 USA study sites showed significant HbA1c decrease of 1.4%±1.3%, from 9.4%±1.0% at baseline to 8.0%±1.2% after device use, p<0.0001 (mean±SD).Meta-analysis of medical records from USA and Canada sites (n=191) showed HbA1c significantly decreased by 1.1%±0.14% (mean±SE), from baseline 9.2%±1.0% to 8.1%±1.1%, p≤0.0001, with moderate to high heterogeneity between sites (Q=43.9, I
conclusionsIn a real-world retrospective USA study and a meta-analysis of a larger USA and Canada cohort, HbA1c significantly reduced in basal insulin-treated type 2 diabetes, without bolus insulin initiation and following the commencement of flash glucose monitoring technology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.